Benzinga
Benzinga
Benzinga
mardi, septembre 15

BeOne Medicines Ltd

ONCNASDAQ
Trade with Public
Trade with Public
$348.13
-5.70-1.61%
Dern. MÀJ: Sep 15, 12:05 PM
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

BeOne Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for BeOne Medicines (ONC).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

2S.Buy
14Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$386Upside to Avg. PT+10.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 10, 2026BarclaysEtzer DaroutPT RaiseOverweight$407→$415
Aug 6, 2026TD CowenYaron WerberPT RaiseBuy$424→$454
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $424 to $454.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $396 to $405.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved